ACRV

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology therapeutics for patients whose tumors are predicted to respond based on molecular biomarkers. Headquartered in Watertown, Massachusetts, the company utilizes its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to identify which patients are most likely to benefit from its drug candidates. The platform analyzes protein-based biology to match patients with targeted therapies, addressing a key challenge in oncology drug development. The company's lead product candidate, ACR-368, is a selective small molecule inhibitor of CHK1 and CHK2 proteins currently in Phase 2 clinical trials for platinum-resistant ovarian cancer and other solid tumors. Acrivon's AP3 platform has identified a biomarker signature that predicts patient response to ACR-368, enabling the company to pursue a biomarker-directed development strategy. The company also advances ACR-1178, a PKMYT1 inhibitor in preclinical development. Founded in 2020, Acrivon completed its initial public offering in November 2023, raising capital to advance its clinical programs. The company's precision medicine approach aims to improve clinical trial success rates and therapeutic outcomes by selecting patients based on molecular predictors of response rather than traditional tissue-of-origin classifications. Acrivon collaborates with leading cancer centers to validate its platform and advance its pipeline of targeted oncology therapeutics.